The Indian stock market began the day on a quiet footing, yet one SME debut managed to stand out—Mahamaya Lifesciences. The company entered the public markets today with its IPO listing on the BSE SME platform, opening to a gentle but firm start that quickly drew investor interest.
While the broader mood in the Indian stock market stayed soft, the newly listed Mahamaya Lifesciences shares carved out their own path, beginning slightly above the issue price and extending gains soon after.
Market Performance: A Mild Debut Followed by Quick Gains
The listing tone was restrained, but far from dull.
Mahamaya Lifesciences shares opened at ₹116, giving the SME IPO a 1.75% premium over its issue price of ₹114.
Within the first phase of trade, the stock hit its 5% upper circuit at ₹121.80, signalling immediate buying interest even as the broader market drifted lower.
By around midday, Mahamaya Lifesciences traded at ₹116.05, holding on to gains while benchmark indices hovered in the red. The day’s movement showed that despite a quiet debut, investors were willing to test the stock on listing day.
Main News: Mahamaya Lifesciences IPO Subscription & Structure
The public issue of Mahamaya Lifesciences ran from November 11 to November 13, attracting interest across segments. The IPO structure included both a fresh issue and an offer for sale.
IPO Breakdown
- Fresh issue: 56,38,800 equity shares
- Offer for sale (OFS): 5,40,000 equity shares
- Total subscription: 1.6 times
- Retail subscription: 1 time
The subscription numbers painted a picture of steady demand, especially from retail investors who fully subscribed to their portion.
Company Details: What Mahamaya Lifesciences Does
Mahamaya Lifesciences operates in the pesticide formulations space.
The company makes and supplies a range of bulk formulations used across the agrochemical industry. Its customer base includes both Indian players and multinational corporations, giving it a diversified footprint.
The company’s revenue and profit figures over the recent financial years reflect consistent performance and expansion across operations.
Key Financials
Revenue from Operations
- FY23: ₹137.1 crore
- FY24: ₹161.6 crore
- FY25: ₹264.2 crore
- Q1 FY25 (3 months ended June 30, 2025): ₹83 crore
Profit After Tax
- FY23: ₹3.75 crore
- FY24: ₹5.22 crore
- FY25: ₹12.94 crore
- Q1 FY25: ₹4.10 crore
These numbers show the company’s rising scale of business over the past three financial periods, along with healthy profitability momentum in early FY25.
Summary: What Today’s Listing Means for Investors
- Mahamaya Lifesciences IPO listed at ₹116, a 1.75% premium.
- Stock moved up to its 5% upper circuit at ₹121.80 shortly after the debut.
- The IPO was subscribed to 1.6 times, with retail investors subscribing to their portion fully.
- The company offers pesticide formulation products to Indian and multinational agrochemical firms.
- Financials show growing revenue from ₹137.1 crore in FY23 to ₹264.2 crore in FY25.
- Listing happened in a soft, broader market, but the stock still managed to attract buying interest.
Mahamaya Lifesciences’ entry into the SME market adds another name to the growing list of small-cap companies tapping into public market opportunities, marking a notable moment in today’s stock market action.
Easy & quick
Leave A Comment?